Data / Form D filings / CytoDyn Inc.
CytoDyn Inc.: Form D filings
CytoDyn Inc., a pharmaceuticals company in Vancouver, WA, filed 32 Form D notices with the SEC between 2009 and 2026. The latest, on May 11, 2026, reports $18.6 million sold of a $18.6 million offering to 194 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1111 MAIN STREET, SUITE 660, Vancouver, WA, 98660
- Phone
- (360) 980-8524
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1175680
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | New notice | $18,600,392 | $18,600,392 | 194 | Jan 30, 2026 | sec.gov | |
| Sep 19, 2022 | Amendment | $21,771,535 | $21,771,535 | 166 | Apr 7, 2022 | sec.gov | |
| Apr 25, 2022 | Amendment | Indefinite | $1,890,000 | 21 | Apr 7, 2022 | sec.gov | |
| Apr 22, 2022 | New notice | Indefinite | $1,890,000 | 21 | Apr 7, 2022 | sec.gov | |
| Dec 3, 2021 | New notice | $53,593,700 | $11,361,000 | $42,232,700 | 118 | Nov 17, 2021 | sec.gov |
| Sep 16, 2021 | New notice | $25,220,000 | $2,872,000 | $22,348,000 | 6 | Aug 31, 2021 | sec.gov |
| Dec 16, 2020 | New notice | $1,176,000 | $0 | $1,176,000 | 0 | Yet to occur | sec.gov |
| Dec 16, 2020 | New notice | $1,000,000 | $1,000,000 | 1 | Nov 7, 2020 | sec.gov | |
| Apr 7, 2020 | Amendment | $11,355,000 | $7,570,000 | $3,785,000 | 3 | Jan 31, 2020 | sec.gov |
| Mar 30, 2020 | New notice | $1,157,625 | $882,000 | $275,625 | 1 | Mar 13, 2020 | sec.gov |
| Feb 14, 2020 | New notice | $7,570,000 | $7,570,000 | 3 | Jan 31, 2020 | sec.gov | |
| Nov 12, 2019 | Amendment | $20,000,000 | $7,788,000 | $12,212,000 | 61 | Mar 20, 2019 | sec.gov |
| Apr 2, 2019 | New notice | $5,000,000 | $3,246,000 | $1,754,000 | 53 | Mar 20, 2019 | sec.gov |
| Sep 10, 2018 | New notice | $25,000,000 | $13,199,385 | $11,800,615 | 119 | Aug 28, 2018 | sec.gov |
| Feb 28, 2018 | Amendment | $17,643,452 | $17,643,452 | 200 | Nov 2, 2017 | sec.gov | |
| Nov 16, 2017 | New notice | $15,000,000 | $1,199,900 | $13,800,100 | 20 | Nov 2, 2017 | sec.gov |
| Jun 14, 2017 | New notice | $15,000,000 | $1,150,000 | $13,850,000 | 2 | May 31, 2017 | sec.gov |
| May 11, 2016 | New notice | $10,000,000 | $4,301,500 | $5,698,500 | 41 | Apr 26, 2016 | sec.gov |
| Feb 23, 2016 | Amendment | $33,268,465 | $33,268,465 | 261 | Jun 30, 2015 | sec.gov | |
| Oct 5, 2015 | New notice | $3,981,050 | $2,693,800 | $1,287,250 | 67 | Sep 21, 2015 | sec.gov |
| Jul 14, 2015 | New notice | $30,000,000 | $1,972,500 | $28,027,500 | 30 | Jun 30, 2015 | sec.gov |
| May 14, 2015 | New notice | $4,000,000 | $3,281,050 | $718,950 | 54 | Apr 30, 2015 | sec.gov |
| Oct 29, 2013 | Amendment | $14,500,000 | $14,500,000 | 170 | Sep 25, 2013 | sec.gov | |
| Sep 25, 2013 | New notice | $10,010,000 | $3,207,260 | $6,802,740 | 56 | Sep 25, 2013 | sec.gov |
| Aug 5, 2013 | Amendment | $10,000,000 | $7,788,250 | $2,211,750 | 34 | Oct 1, 2012 | sec.gov |
| Feb 15, 2013 | Amendment | $10,000,000 | $5,908,250 | $4,091,750 | 15 | Oct 1, 2012 | sec.gov |
| Oct 16, 2012 | New notice | $7,000,000 | $5,700,000 | $1,300,000 | 14 | Oct 1, 2012 | sec.gov |
| Sep 5, 2012 | New notice | $575,500 | $575,500 | 2 | Jul 27, 2012 | sec.gov | |
| Jan 17, 2012 | New notice | $3,000,000 | $2,996,082 | $3,918 | 86 | Dec 7, 2011 | sec.gov |
| Aug 24, 2010 | New notice | $2,000,000 | $0 | $2,000,000 | 0 | Yet to occur | sec.gov |
| Nov 19, 2009 | New notice | $1,000,000 | $250,000 | $750,000 | 1 | Nov 3, 2009 | sec.gov |
| Oct 20, 2009 | New notice | $2,000,000 | $455,000 | $1,545,000 | 13 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jacob P. Lalezari | Executive Officer | |
| Robert E. Hoffman | Executive Officer | |
| Tyler Blok | Executive Officer | |
| Lishomwa C. Ndhlovu, M.D., Ph.D. | Director | |
| Karen J. Brunke, Ph.D. | Director | |
| Ryan M. Dunlap | Director | |
| Tanya D. Urbach | Director | |
| Stephen M. Simes | Director |
Other pharmaceuticals companies in Washington that filed recently
- Aptevo Therapeutics Inc. $3.5 million · Aug 26, 2026
Every Form D from the week of May 11, 2026 · All recent filings in Washington · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what CytoDyn Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.